Almawash S
Cancers (Basel). 2025; 17(5).
PMID: 40075727
PMC: 11899125.
DOI: 10.3390/cancers17050880.
Zielinska M, Ciazynska M, Sulejczak D, Rutkowski P, Czarnecka A
Biomolecules. 2025; 15(2).
PMID: 40001572
PMC: 11853485.
DOI: 10.3390/biom15020269.
Mei T, Ye T, Huang D, Xie Y, Xue Y, Zhou D
Cell Oncol (Dordr). 2024; 47(6):2049-2071.
PMID: 39565509
DOI: 10.1007/s13402-024-01009-6.
Yao H, Huang C, Zou J, Liang W, Zhao Y, Yang K
J Extracell Vesicles. 2024; 13(7):e12484.
PMID: 39041344
PMC: 11263977.
DOI: 10.1002/jev2.12484.
Hu J, Wang S, Zhang X, Yan W, Liu H, Chen X
Arch Toxicol. 2024; 98(10):3425-3438.
PMID: 38992170
DOI: 10.1007/s00204-024-03820-4.
Multimodal HLA-I genotype regulation by human cytomegalovirus US10 and resulting surface patterning.
Gerke C, Bauersfeld L, Schirmeister I, Mireisz C, Oberhardt V, Mery L
Elife. 2024; 13.
PMID: 38900146
PMC: 11189632.
DOI: 10.7554/eLife.85560.
Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement.
Hopkins J, MacLachlan B, Harper S, Sewell A, Cole D
Discov Immunol. 2024; 1(1):kyac001.
PMID: 38566908
PMC: 10917088.
DOI: 10.1093/discim/kyac001.
Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9.
Chariou P, Minnar C, Tandon M, Guest M, Chari R, Schlom J
PLoS One. 2024; 19(3):e0287733.
PMID: 38427670
PMC: 10906908.
DOI: 10.1371/journal.pone.0287733.
Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.
Versluis J, Hoefsmit E, Shehwana H, Dimitriadis P, Sanders J, Broeks A
Cancer Immunol Immunother. 2024; 73(2):28.
PMID: 38280045
PMC: 10821835.
DOI: 10.1007/s00262-023-03581-6.
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.
Kumar S, Chatterjee M, Ghosh P, Ganguly K, Basu M, Ghosh M
Genes Dis. 2023; 10(4):1318-1350.
PMID: 37397537
PMC: 10311058.
DOI: 10.1016/j.gendis.2022.07.024.
Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions.
Sammarco E, Manfredi F, Nuzzo A, Ferrari M, Bonato A, Salfi A
Cancers (Basel). 2023; 15(12).
PMID: 37370782
PMC: 10296725.
DOI: 10.3390/cancers15123172.
The role of mitochondria in the resistance of melanoma to PD-1 inhibitors.
Du F, Yang L, Liu J, Wang J, Fan L, Duangmano S
J Transl Med. 2023; 21(1):345.
PMID: 37221594
PMC: 10207731.
DOI: 10.1186/s12967-023-04200-9.
Novel strategies for cancer immunotherapy: counter-immunoediting therapy.
Liu S, Sun Q, Ren X
J Hematol Oncol. 2023; 16(1):38.
PMID: 37055849
PMC: 10099030.
DOI: 10.1186/s13045-023-01430-8.
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired.
Marei H, Hasan A, Pozzoli G, Cenciarelli C
Cancer Cell Int. 2023; 23(1):64.
PMID: 37038154
PMC: 10088229.
DOI: 10.1186/s12935-023-02902-0.
Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer.
Jie C, Li R, Cheng Y, Wang Z, Wu Q, Xie C
Front Immunol. 2023; 14:1122352.
PMID: 36875059
PMC: 9981667.
DOI: 10.3389/fimmu.2023.1122352.
An L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy.
Lin J, Liu J, Hao S, Lan B, Zheng X, Xiong J
Front Immunol. 2022; 13:1022598.
PMID: 36505399
PMC: 9727402.
DOI: 10.3389/fimmu.2022.1022598.
Partial peptide dissociation and binding groove plasticity in two major histocompatibility complex class I alleles - differences between alleles force field and sampling effects.
Wingbermuhle S, Schafer L
RSC Adv. 2022; 12(46):29908-29914.
PMID: 36321080
PMC: 9580618.
DOI: 10.1039/d2ra05324a.
Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.
Zhou X, Ni Y, Liang X, Lin Y, An B, He X
Front Immunol. 2022; 13:915094.
PMID: 36189283
PMC: 9520263.
DOI: 10.3389/fimmu.2022.915094.
Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications.
Fang P, Zhou J, Liang Z, Yang Y, Luan S, Xiao X
Front Immunol. 2022; 13:975986.
PMID: 36119033
PMC: 9478443.
DOI: 10.3389/fimmu.2022.975986.
LAMTOR1 degrades MHC-II via the endocytic in hepatocellular carcinoma.
Wu B, Wang Q, Li B, Jiang M
Carcinogenesis. 2022; 43(11):1059-1070.
PMID: 36070764
PMC: 9890926.
DOI: 10.1093/carcin/bgac075.